April Global News
The Drugs for Neglected Diseases initiative (DNDi; Geneva, Switzerland) received ?5 million from Spain's Agencia Espa?ola de Cooperaci?n Internacional, based in Madrid, to aid in the research and development of new, effective, and affordable drugs for neglected diseases, including Chagas disease, human African trypanosomiasis, and malaria. DNDi plans to develop two new malaria drugs by the end of the year and is looking to create between six and eight new drugs for neglected diseases by 2014.
April Global News
• The Drugs for Neglected Diseases initiative (DNDi; Geneva, Switzerland) received €5 million from Spain's Agencia Española de Cooperación Internacional, based in Madrid, to aid in the research and development of new, effective, and affordable drugs for neglected diseases, including Chagas disease, human African trypanosomiasis, and malaria. DNDi plans to develop two new malaria drugs by the end of the year and is looking to create between six and eight new drugs for neglected diseases by 2014.
• Thailand's Public Health Minister Chaiya Sasomsap announced that Siriwat Thiptharadon, head of Thailand's Food and Drug Administration, was removed from his position and moved instead to an inactive post. Thiptharadon is known for establishing the former government's compulsory license program, which aimed to make drugs more affordable and is now vulnerable to a committee review under Sasomsap's orders. Chatree Banchuen was named secretary general of Thailand's FDA following Thiptharadon's departure, but resigned a week later citing that he was "uncomfortable with the politics."
• Kampala, Uganda's Mulago Hospital, a 1500-bed facility affiliated with Makerere University, is the home of the first Health Volunteers Overseas (HVO; Washington, DC) hematology training program, created by HVO and the American Society of Hematology (Washington, DC). The program's purpose is to bolster the hematology training of clinicians, lab technicians, technologists, and students.
• The University of Portsmouth (Hampshire, UK) is collaborating with brain tumor charity Brainstrust (Hampshire, UK) among others to create the UK's first dedicated laboratory-based brain tumor research center. Brain tumors are the most common form of cancer in people under 40 and the most common cause of death in children after accidents.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
